61 results about "Ocular inflammation" patented technology

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

This invention provides a traditional Chinese medicine composition and its application in the preparation of a topical herbal eye patch for treating thyroid eye diseases, belonging to the field of biomedical technology. The herbal composition consists of *Gynostemma pentaphyllum*, peppermint, *Platycladus orientalis* leaves, borneol, cicada slough, *Astragalus membranaceus*, *Selaginella tamariscina*, *Pteris vittata*, *Scutellaria baicalensis*, apricot leaf, and *Ipomoea aquatica*. Using this herbal composition as raw material, a topical herbal eye patch is prepared. This patch acts directly on acupoints and skin around the eyes, allowing the medicinal properties to penetrate the skin and reach the eye system, achieving the effects of promoting blood circulation, clearing heat and detoxifying, invigorating qi and unblocking meridians, reducing swelling and improving vision. It is suitable for the treatment of thyroid-related eye diseases. This invention's topical herbal eye patch can effectively improve clinical symptoms such as exophthalmos and eye inflammation in patients with thyroid eye diseases, positively impacting their quality of life and effectively improving the clinical treatment efficacy of this disease. The topical herbal eye patch provided by this invention can be further promoted and applied in the clinical treatment of thyroid eye diseases.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

The invention relates to the technical field of biological medicines, and discloses a pharmaceutical composition applied to eye inflammation treatment. The invention provides a pharmaceutical composition applied to treatment of eye inflammation. The structural formula of the active ingredient of the pharmaceutical composition is # imgabs0. The pharmaceutical composition applied to treatment of eye inflammation provided by the invention has a good treatment effect on eye inflammation.

The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.

The invention relates to the technical field of biological medicine, and discloses a tobramycin nano transfer body as well as a preparation method and application thereof. The invention provides a preparation method of a tobramycin nano transfer body, which specifically comprises the following steps: uniformly mixing lipid, a surfactant, xylooligosaccharide and an alcohol solvent, evaporating to remove the alcohol solvent to obtain a film, and hydrating the film with a tobramycin-PBS buffer solution to obtain a suspension; and then carrying out ultrasonic treatment and graded filtration on the suspension to obtain the tobramycin nano transfer body. The tobramycin nano transfer body has the advantages of high stability, capability of effectively improving the permeability of a hydrophilic drug penetrating through a biological barrier, small particle size, small PDI and the like. The tobramycin-in-situ gel prepared by using the tobramycin nano transfer body has good biocompatibility, stable drug loading capacity and controllable drug release performance, can penetrate cornea to reach a focus to play a targeting role, and can be applied to preparation of external preparations for treating ocular inflammation.

The invention discloses eye health care liquid based on cortex berberidis and saffron crocus extracts and a preparation method of the eye health care liquid, and relates to the technical field of traditional Chinese medicine preparations and eye health care, in particular to the eye health care liquid based on the cortex berberidis and saffron crocus extracts and the preparation method of the eye health care liquid. According to the eye health-care liquid, a cortex berberidis extract and a saffron crocus extract are used as main active ingredients, a fructus lycii extract, a radix stemonae extract, a mint extract, a honeysuckle flower extract and other functional ingredients are used as auxiliary ingredients, and sodium hyaluronate, taurine and vitamin B6 are added to enhance the moisturizing, anti-oxidation and metabolic regulation effects. The preparation method comprises the steps of raw material extraction, extract concentration, auxiliary material mixing and pH adjustment, filtration and sterilization and the like. The product is suitable for eye atomization application, has the effects of relieving eye inflammation, improving microcirculation, relieving dryness, redness and swelling and the like, meanwhile strictly controls heavy metal and microbiological indexes, and guarantees use safety.

The invention belongs to the technical field of probiotics, and particularly relates to lactobacillus reuteri HuYan with an eye protection effect and application of the lactobacillus reuteri HuYan. According to the invention, a novel lactobacillus reuteri HuYan strain is separated from feces of a healthy infant in Guangzhou city, Guangdong province, and the lactobacillus reuteri HuYan strain can significantly reduce vascular hyperplasia and cell apoptosis of eyes, inhibit eye shrinkage, reduce the number of neutrophils in the eyes, reduce the content of levodopa and increase the content of levo5-hydroxytryptamine. Therefore, the strain can be applied to prevention and treatment of eye vascular dysplasia related diseases, protection of intraocular cells to avoid apoptosis, improvement or prevention of eye shrinkage and alleviation of eye inflammation, has positive significance in protection of eye tissues and maintenance of normal physiological status of eyes, is expected to be used in the fields related to prevention and treatment of eye diseases, and has wide application prospects. Wide application prospects are realized in the field of treating and preventing eye diseases.

The invention belongs to the technical field of pet supplies, and particularly discloses a composition and application thereof in preparation of a product for reducing pet tear stains, the composition can effectively reduce the tear stains, and the composition, the composition and the product all have certain anti-inflammatory effects and jointly reduce tear secretion and inflammation-related tear stains. Meanwhile, the althaea rosea extract can improve the availability of hydroxytyrosol and fucoidan polysaccharide sulfate, improve eye microcirculation and relieve eye fatigue and dryness, fucoidan polysaccharide sulfate reduces iron elements entering tears through portal vein circulation and blocks generation of porphyrin-iron compounds, hydroxytyrosol improves metabolism and accelerates ferriporphyrin metabolism, and the effect of improving eye quality is achieved. The althaea officinalis extract promotes biliary secretion and accelerates ferriporphyrin metabolism, the synergistic interaction of the althaea officinalis extract, the althaea officinalis extract, the ferriporphyrin and the althaea officinalis extract can effectively reduce formation of tear stains, the risk of eye inflammation and bacterial infection is reduced, immunity can be improved, blood circulation can be promoted, and finally the pet is helped to keep a clean and healthy eye environment.

Chlorogenic acid is used in the preparation of a drug for treating and / or preventing ocular inflammation. Chlorogenic acid can significantly alleviate symptoms of uveitis and scleritis, and has good treatment effects on ocular inflammation.

The present invention relates to ophthalmic compositions comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, particularly varenicline, mecamillamine, and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts thereof, and choline-containing phospholipids, salts and derivatives thereof. Of these, choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g., lecithin with a phosphatidylcholine content of 80% by weight or more, e.g., soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine are particularly preferred.

The application discloses application of NSUN2 in treatment of wet age-related macular degeneration. The application research finds that inhibition or silencing of the NSUN2 gene can significantly inhibit ocular neovascularization, reduce ocular inflammatory response, and effectively inhibit the development of subretinal fibrosis, and the result shows that the NSUN2 can be used as a potential target for treating wet age-related macular degeneration. Therefore, the application provides a new strategy for treating wet age-related macular degeneration.

Provided herein is an ophthalmic composition, comprising an aqueous solution, comprising (i) a pharmaceutically effective amount of a phosphorylcholine-tuftsin conjugate, (ii) between 0.1 and 5% weight per weight (w / w) of a viscosity enhancer, and (iii) between 0.1 and 5% w / w of a mucoadhesive polymer. Provided herein is a synergistic preservative composition comprising a phosphorylcholine-tuftsin conjugate and BAK. Furthermore, a pharmaceutical composition (e.g. ophthalmic composition) comprising an effective amount of the preservative composition is also povided. A method of using the ophthalmic composition such as for treating or preventing ocular inflammation in a subject in need thereof is also provided. Furthermore, method of using the ophthalmic composition such as for enhancing ocular bioavailability of a phosphorylcholine-tuftsin conjugate within a subject is also provided.

Ophthalmic compositions for removing biofilms from the eye and for treating ocular inflammation, blepharitis, and dry eye are disclosed, comprising α-amylase, and optionally other ingredients.

Dendrimer compositions and methods for the treatment of one or more inflammatory and / or angiogenic diseases and / or disorders of the eye include hydroxyl-terminated dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of the diseases of the eye, and / or for diagnosing the diseases and / or disorders of the eye. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be VEGFR tyrosine kinase inhibitors including sunitinib or analogues thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia / macrophages in retina / choroid.

The invention discloses an eye care spray containing a leech extract, and relates to the technical field of cosmetics. The formula contains the leech extract, the sodium hyaluronate and the carboxymethyl deacetylated chitin, and the leech extract can promote regeneration and self-repair of eye cells and promote cell growth and collagen synthesis in eye tissues; the carboxymethyl deacetylated chitin can prevent eye inflammatory response, and the sodium hyaluronate can replenish water, preserve moisture and prevent and relieve eye interference. By utilizing the synergistic effect of the leech extract, the sodium hyaluronate and the carboxymethyl deacetylated chitin, the three effects of moisturizing eyes, resisting inflammation and repairing are integrated. Besides, the product adopts a mild anti-corrosion system, the product can reach the mildness of eye drops on the premise that the product quality is guaranteed and the anti-corrosion effect is good, and the preparation method of the spray is simple in operation, low in cost and worthy of popularization, and the needed materials are simple and easy to obtain.

The present application relates to a kind of eye drops for treating dry eye and its preparation method, eye drops include by mass percentage: 0.05-0.5% of the extract of Monarda, 0.1-0.4% of silk fibroin nanoparticles coated with lutein, 0.1%-0.5% of chondroitin sulfate, 0.9-1.0% of sodium chloride, 0.05%-0.1% of poloxamer, 0.01%-0.1% of EDTA, phosphate buffer and water;The particle size of silk fibroin nanoparticles coated with lutein is 50-300nm, water is pharmaceutical sterile water, and the pH of eye drops is adjusted to 7.0-7.8 by phosphate buffer solution.The eye drops of the present application can effectively relieve dry eye symptoms, provide long-term wetting and protection, while reducing ocular inflammation and oxidative stress, can promote the repair of corneal injury, and effectively reduce the expression level of inflammatory factors, and high use safety.

Methods and pharmaceutical compositions for treating ocular disease are disclosed, including ocular disease involving ocular vascular permeability or ocular inflammation. In various aspects and embodiments, the invention comprises administering about 1 μg to about 1 mg of collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to about once every two years. In various embodiments, the methods and compositions provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.

The present invention relates to use of a recombinant type III humanized collagen and a composition comprising the same in an eye. Provided are use of a recombinant type III humanized collagen in the preparation of a product for preventing and / or treating eye inflammation, a composition comprising the recombinant type III humanized collagen, and use of the composition in the preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant type III humanized collagen and the composition comprising the same can significantly promote the renewal and repair of corneal epithelial cells, and can also inhibit the release of inflammatory mediators, enhancing the ocular tissue barrier, enhancing tear film stability, and alleviating eye inflammation and eye dryness.

The application discloses a synthesis method and application of a cyclic hexapeptide scleramide, and the structure of the cyclic hexapeptide scleramide is as follows: the cyclic hexapeptide scleramide is coupled with FMOC-Gln(trt)-N-Me-Phe, FMOC-glycine, FMOC-N-methyl-L-phenylalanine and FMOC-L-phenylalanine in the order from the C terminal to the N terminal of the cyclic peptide sequence of the cyclic hexapeptide scleramide in the presence of a condensation reagent and an organic base by using glycine-resin, and then the protecting group is removed by using an organic base, so that the amino acid sequence, the cyclization mode and the modification site can be accurately controlled through solid-phase / liquid-phase synthesis technology, the efficient preparation of the cyclic hexapeptide scleramide compound is realized, and the limitation of a natural source is broken; meanwhile, the compound has significant anti-inflammatory activity, and provides an alternative compound for developing a new eye inflammation drug.

The invention discloses pranoprofen eye drops and a preparation method thereof, and the pranoprofen eye drops are prepared from the following components in parts by weight: 20-30 parts of pranoprofen, 20-30 parts of glucocorticoid, 5-20 parts of taurine, 5-20 parts of glucose, 5-20 parts of sodium hyaluronate, 5-20 parts of polyvinyl alcohol, 5-20 parts of boric acid and 5-20 parts of a surfactant. The sodium hyaluronate and the polyvinyl alcohol are added into the eye drops, and the sodium hyaluronate is a viscoelastic glycoprotein and has lubricating and anti-inflammatory effects; polyvinyl alcohol is artificial tears and is mainly used for treating eye dryness and foreign body sensation caused by xerophthalmia, the situation that due to long-term use, normal flora imbalance of eyes is caused, the symptom of eye inflammation is aggravated, and the experience feeling of a user is improved is avoided; the taurine and the glucocorticoid are added into the eye drops, and the taurine has the effects of clearing away heat and toxic materials and relieving asthenopia, so that the comfort of the eye drops dropped into eyes is improved.

Dendrimer compositions and methods for treating one or more ocular inflammatory and / or angiogenic diseases and / or conditions, including hydroxyl-terminated dendrimers complexed or conjugated to one or more active agents for treating or reducing one or more symptoms of an ocular disease, and / or for diagnosing an ocular disease and / or condition. The dendrimers can include one or more ethylenediamine core poly(amidoamine) (PAMAM) hydroxyl-terminated generation 4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agent can be a VEGFR tyrosine kinase inhibitor, including sunitinib or an analog thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia / macrophages in the retina / choroid.

The present technology comprises ocular cooling devices for reducing and / or controlling an eye temperature level. The ocular cooling devices may be useful in methods including, but not limited to, treating or preventing an ocular pain, an ocular inflammation, or an intraocular pressure in a subject in need thereof relative to a control. In some embodiments, the ocular cooling devices are portable.